Vertex gets more precise with Arbor in expanded gene editing pact
Feng Zhang’s Arbor Biotechnologies is expanding its alliance with Vertex Pharmaceuticals, but is staying mum on financials this time around.
The CRISPR gene editing startup, which has been relatively quiet aside from partnership and capital-raising news since its March 2018 unveiling, is providing its Boston partner with access to precision editing technology for in vivo genetic medicines for “up to three diseases.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.